SUPN FY 2015 Earnings — Supernus Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

SUPNSupernus Pharmaceuticals, Inc.

$3B

FY 2015 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$144M+18.3% YoY

Gross Profit

$136M94.2% margin

Operating Income

$18M12.2% margin

Net Income

$14M9.7% margin

EPS (Diluted)

$0.28

Cash Flow

Operating Cash Flow

$32M

Free Cash Flow

$30M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$189M

Total Liabilities

$70M

Stockholders' Equity

$119M

Cash & Equivalents

$62M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$144M	$122M	+18.3%
Gross Profit	$136M	$116M	+17.0%
Operating Income	$18M	$24M	-27.1%
Net Income	$14M	$20M	-29.5%